ESWL

The Worldwide Kidney Stone Retrieval Devices Industry is Expected to Reach $3.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.

Key Points: 
  • Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.
  • Considerably smaller ureter scopes, quartz fibers, and lithotripter probes have made the extraction of kidney stones from previously unreachable locations far safer than traditional surgical options.
  • For instance, the Dretler stone cone is one innovation that inhibits stone migration during the treatment.
  • The demand for kidney stone retrieval devices was uneven, with installation delays and a decline in manufacturing during the pandemic.

ADVANCED MEDTECH ACQUIRES WIKKON, STRENGTHENING ITS MARKET LEADING POSITION IN UROLOGY MEDICAL DEVICES

Retrieved on: 
Tuesday, September 13, 2022

Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.

Key Points: 
  • Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.
  • Abel Ang, Group Chief Executive of Advanced MedTech, said: We are now uniquely placed to aggressively grow in Chinas sizeable market, which is best served by domestically produced devices.
  • Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and contract manufacturing services.
  • Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world.

$1.87 Billion Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecasts, 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022

The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Global Lithotripsy Devices Market was valued at USD 1.44 billion in 2021, growing at a CAGR of 4.35% during the forecast period from 2022 to 2027, to reach USD 1.87 billion by 2027.
  • Such technological advancement in the field of Lithotripsy Devices is likely to boost the Global Lithotripsy Devices Market during the forecast period.
  • Which are the regions and countries where companies should have concentrated on opportunities for Lithotripsy Devices market growth in the coming future?

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Retrieved on: 
Wednesday, August 3, 2022

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23

Retrieved on: 
Monday, July 18, 2022

LYON, France, July 18, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has released its proposed outpatient prospective payment system (OPPS) reimbursement rule for calendar year 2023 (CY23).

Key Points: 
  • For a hospital performing a Focal One HIFU prostate ablation on an outpatient basis, the proposed rule would increase the reimbursement level to an Ambulatory Payment Classification (APC) level 6, as compared to APC level 5 currently.
  • The increase to APC level 6 has positive implications for patients beyond Medicare since many commercial payors have begun to cover focal HIFU for their members.
  • Commercial payment and access policies are influenced by Medicare policy and reimbursement decisions.
  • Comments on the proposed rule are due by September 30, and the final rule is anticipated in November.

EDAP’s Focal One® HIFU to be Showcased at Two Major Robotics & Urology International Congresses

Retrieved on: 
Tuesday, June 28, 2022

LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its participation to two major forthcoming international robotics and urology congresses:

Key Points: 
  • Focal One Robotic Focal HIFU will be featured and demonstrated at EDAPs booth #C26 for the duration of the event.
  • Congress presentation topics will include use of HIFU focal therapy in prostate cancer along with supportive HIFU case reviews.
  • Focal One Robotic Focal HIFU will be presented in the Friday Focal Therapy and Prostate Cancer plenary presentation given by Brian Miles, MD, FACS, Professor of Urology, Weill Cornell Medical College and Vice-Chair Dept.
  • Focal One Robotic Focal HIFU will also be presented by Ryan Rhodes, CEO EDAP USA in the SRS Innovative Technologies Session held on Sunday.

EDAP holds a Symposium at 6th European Endometriosis Congress

Retrieved on: 
Tuesday, June 14, 2022

EDAP will occupy booth #23 during the congress.

Key Points: 
  • EDAP will occupy booth #23 during the congress.
  • Details of the presentation is as follows:
    The European Endometriosis Congress, a meeting of the European Endometriosis League (EEL), represents a gathering of all healthcare providers who deal with endometriosis, including surgeons, gynecologists, fertility specialists, radiologists, biologists and others.
  • The aim of the congress is to allow these different specialties to work together and learn from one another.
  • The Congress provides opportunities for networking and the sharing of the latest research and news about innovative new technology for the treatment of endometriosis.

EDAP Announces Multiple Oral Presentations at the 21st International Symposium on Therapeutic Ultrasound

Retrieved on: 
Monday, June 6, 2022

LYON, France, June 6, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21st Annual International Symposium on Therapeutic Ultrasound (ISTU), which is being held June 7-10, in Toronto and virtually.

Key Points: 
  • LYON, France, June 6, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21st Annual International Symposium on Therapeutic Ultrasound (ISTU), which is being held June 7-10, in Toronto and virtually.
  • Details of the presentations are as follows:
    Transrectal High-intensity focused ultrasound (TR-HIFU) for the management of rectal Deep Infiltrating Endometriosis: Results of phase I clinical trials
    Pr.
  • Established in 2001, the International Society for Therapeutic Ultrasound (ISTU) provides a foundation for international collaboration on issues related to therapeutic ultrasound.
  • ISTU's principal mission is to foster the diffusion of knowledge concerning the scientific and clinical aspect of therapeutic ultrasound.

EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

Retrieved on: 
Tuesday, May 10, 2022

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP to Showcase its Focal One® Platform at the Annual Meeting of the American Urological Association (AUA)

Retrieved on: 
Thursday, May 5, 2022

LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held May 13th through 15th in New Orleans.

Key Points: 
  • Focal One will be a featured topic at AUA, during both plenary presentations and instructional courses.
  • Several notable presentations will be given by leading academic centers describing the growing clinical acceptance of the role of focal therapy in the management of prostate cancer.
  • Ryan Rhodes, CEO of EDAP U.S., said, We are very pleased to have such a notable presence at AUA, the most high-profile urology meeting of the year.
  • Ongoing Focal One and ExactVu Micro-Ultrasound hands-on simulations will be provided to urologists at the EDAP Focal One booth (#117) throughout the meeting.